Published in Clin Exp Immunol on January 01, 2000
IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. J Clin Invest (2002) 1.74
Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27. Clin Dev Immunol (2010) 1.59
Immunotherapy of cancer by IL-12-based cytokine combinations. Expert Opin Biol Ther (2007) 1.48
Tumor cells and tumor-associated macrophages: secreted proteins as potential targets for therapy. Clin Dev Immunol (2011) 1.41
Interleukin 12: still a promising candidate for tumor immunotherapy? Cancer Immunol Immunother (2014) 1.17
Central role of IFNgamma-indoleamine 2,3-dioxygenase axis in regulation of interleukin-12-mediated antitumor immunity. Cancer Res (2009) 1.13
Networking the host immune response in Plasmodium vivax malaria. Malar J (2013) 1.02
Deregulated cytokine network and defective Th1 immune response in multiple myeloma. Clin Exp Immunol (2001) 0.88
Phase 2 study of pegylated liposomal doxorubicin in combination with interleukin-12 for AIDS-related Kaposi sarcoma. Blood (2007) 0.83
Oncolytic adenovirus expressing IL-23 and p35 elicits IFN-γ- and TNF-α-co-producing T cell-mediated antitumor immunity. PLoS One (2013) 0.82
Clinical validation of IFNγ/IL-10 and IFNγ/IL-2 FluoroSpot assays for the detection of Tr1 T cells and influenza vaccine monitoring in humans. Hum Vaccin Immunother (2013) 0.78
Defining the Pharmacodynamic Profile and Therapeutic Index of NHS-IL12 Immunocytokine in Dogs with Malignant Melanoma. PLoS One (2015) 0.77
Pluripotent and Multipotent Stem Cells Display Distinct Hypoxic miRNA Expression Profiles. PLoS One (2016) 0.75
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem (1987) 281.19
Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science (1993) 19.80
Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med (1989) 10.60
Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature (1985) 9.18
Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science (1997) 8.95
Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med (1993) 8.76
Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med (1993) 8.03
Interleukin 12 and tumor necrosis factor alpha are costimulators of interferon gamma production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist. Proc Natl Acad Sci U S A (1993) 6.33
IL-12-deficient mice are defective in IFN gamma production and type 1 cytokine responses. Immunity (1996) 6.16
Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature (1997) 6.06
An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet (1997) 5.65
The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol (1998) 5.50
Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc Natl Acad Sci U S A (1990) 4.60
The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science (1994) 4.38
Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med (1993) 4.04
Selective expression of an interleukin-12 receptor component by human T helper 1 cells. J Exp Med (1997) 3.57
Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst (1995) 3.53
Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv Immunol (1998) 3.17
Endogenous interleukin 12 (IL-12) regulates granuloma formation induced by eggs of Schistosoma mansoni and exogenous IL-12 both inhibits and prophylactically immunizes against egg pathology. J Exp Med (1994) 2.99
Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol (1994) 2.68
Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood (1997) 2.66
Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol (1995) 2.36
Effects of interleukin 12 on immune responses and host protection in mice infected with intestinal nematode parasites. J Exp Med (1994) 2.22
Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med (1996) 2.14
Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood (1996) 2.09
Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res (1997) 2.08
Association of tumor necrosis factor (TNF) and class II major histocompatibility complex alleles with the secretion of TNF-alpha and TNF-beta by human mononuclear cells: a possible link to insulin-dependent diabetes mellitus. Eur J Immunol (1993) 1.95
Effects of IL-12 on in vivo cytokine gene expression and Ig isotype selection. J Immunol (1994) 1.92
Prognostic value of intratumoral interferon gamma messenger RNA expression in invasive cervical carcinomas. J Natl Cancer Inst (1998) 1.71
Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res (1994) 1.64
Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. Blood (1997) 1.63
IL-12 deaths: explanation and a puzzle. Science (1995) 1.58
Regulation of NK cell functions by TGF-beta 1. J Immunol (1995) 1.51
Interferon gamma-independent effects of interleukin 12 administered during acute or established infection due to Leishmania major. Proc Natl Acad Sci U S A (1994) 1.47
Genes for chemokines MuMig and Crg-2 are induced in protozoan and viral infections in response to IFN-gamma with patterns of tissue expression that suggest nonredundant roles in vivo. J Immunol (1996) 1.30
Interleukin-11 inhibits macrophage interleukin-12 production. J Immunol (1997) 1.18
Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells. Int Immunol (1995) 1.17
Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. J Immunol (1996) 1.13
The fate of pro-TNF-alpha following inhibition of metalloprotease-dependent processing to soluble TNF-alpha in human monocytes. J Immunol (1997) 1.13
Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer. J Immunol (1997) 1.10
Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. Clin Cancer Res (1998) 1.09
Regulation of alloreactivity in vivo by IL-4 and the soluble IL-4 receptor. J Immunol (1991) 1.02
Role of interferon-gamma in mediating the antitumor efficacy of interleukin-12. J Immunother Emphasis Tumor Immunol (1995) 1.01
Cytokine gene therapy of cancer using interleukin-12: murine and clinical trials. Ann N Y Acad Sci (1996) 0.98
Cell type and stimulus specific regulation of chemokine gene expression. Biochem Biophys Res Commun (1994) 0.98
Predictors of clinical response to interleukin-2--based immunotherapy in melanoma patients: a French multiinstitutional study. J Clin Oncol (1996) 0.97
Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells. Cancer Res (1996) 0.96
Regulation of surface and soluble TNF receptor expression on human monocytes and synovial fluid macrophages by IL-4 and IL-10. J Immunol (1996) 0.96
Interferon gamma-independent rejection of interleukin 12-transduced carcinoma cells requires CD4+ T cells and Granulocyte/Macrophage colony-stimulating factor. J Exp Med (1998) 0.92
Cytokines and cancer. Int Rev Immunol (1998) 0.92
Cancer vaccines: the interleukin 2 dosage effect. Proc Natl Acad Sci U S A (1995) 0.91
Upregulated expression of IL-4 receptors and increased levels of IL-4 in rheumatoid arthritis patients. J Autoimmun (1995) 0.90
The effect of interleukin 12 desensitization on the antitumor efficacy of recombinant interleukin 12. Cancer Res (1997) 0.90
Analysis of interleukin 6 gene expression in cervical neoplasia using a quantitative polymerase chain reaction assay: evidence for enhanced interleukin 6 gene expression in invasive carcinoma. Cancer Res (1994) 0.88
Protective effect of a single interleukin-12 (IL-12) predose against the toxicity of subsequent chronic IL-12 in mice: role of cytokines and glucocorticoids. Blood (1997) 0.85
Production of soluble IL-4 receptors by murine spleen cells is regulated by T cell activation and IL-4. J Immunol (1993) 0.84
Two distinct stimulus-dependent pathways lead to production of soluble murine interleukin-4 receptor. J Immunol (1996) 0.81
In vivo induction of functional Fc gammaRI (CD64) on neutrophils and modulation of blood cytokine mRNA levels in cancer patients treated with G-CSF (rMetHuG-CSF). Br J Haematol (1998) 0.81
In vitro predictors of clinical response in patients receiving interleukin-2-based immunotherapy. Curr Opin Oncol (1993) 0.77
Elevated circulating levels of tumor necrosis factor predict unresponsiveness to treatment with interferon alfa-2b in chronic myelogenous leukemia. J Clin Oncol (1992) 0.76
Soluble interferon-gamma receptor and interferon-gamma in patients undergoing allogeneic bone marrow transplantation for hematological malignancies. Cytokines Cell Mol Ther (1997) 0.76
Soluble interleukin-4 receptor production by murine myeloid progenitor cells: induction by interleukin-6 and interferon-gamma. Cytokine (1993) 0.76
Interleukin 12 is required for the T-lymphocyte-independent induction of interferon gamma by an intracellular parasite and induces resistance in T-cell-deficient hosts. Proc Natl Acad Sci U S A (1993) 6.87
THE MEASUREMENT AND RECORDING OF GASTRODUODENAL BLOOD FLOW IN MAN BY MEANS OF A THERMAL GRADIENTOMETER. J Clin Invest (1942) 5.96
Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie. N Engl J Med (1998) 4.93
Age as prognostic factor in premenopausal breast carcinoma. Lancet (1993) 4.31
Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene (2009) 3.90
Mortality among workers at Oak Ridge National Laboratory. Evidence of radiation effects in follow-up through 1984. JAMA (1991) 3.80
QT interval prolongation as predictor of sudden death in patients with myocardial infarction. Circulation (1978) 3.32
IL-12 increases resistance of BALB/c mice to Mycobacterium tuberculosis infection. J Immunol (1995) 3.29
Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol (1997) 3.08
Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem (1990) 2.99
Stroke in users of low-dose oral contraceptives. N Engl J Med (1996) 2.98
Active immunotherapy of L1210 leukaemia applied after the graft of tumour cells. Br J Cancer (1969) 2.96
Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer (1996) 2.95
Modulation of insulin activities by leptin. Science (1996) 2.92
Secondary plasmodesmata are specific sites of localization of the tobacco mosaic virus movement protein in transgenic tobacco plants. Plant Cell (1992) 2.91
Stimulation of lymphocytes by autologous leukaemic cells in acute leukaemia. Nature (1969) 2.75
Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res (1992) 2.64
The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl (2003) 2.63
Stability increase of the lumbar spine with different muscle groups. A biomechanical in vitro study. Spine (Phila Pa 1976) (1995) 2.62
Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol (2009) 2.60
Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. J Natl Cancer Inst (1994) 2.58
Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet (2004) 2.55
Intensive livestock operations, health, and quality of life among eastern North Carolina residents. Environ Health Perspect (2000) 2.52
Cytoplasmic domain heterogeneity and functions of IgG Fc receptors in B lymphocytes. Science (1992) 2.41
The structure of a human type III Fcgamma receptor in complex with Fc. J Biol Chem (2001) 2.33
Retinal microcirculation in patients with diabetes mellitus: dynamic and morphological analysis of perifoveal capillary network. Br J Ophthalmol (1991) 2.30
Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res (1999) 2.23
"Sniffin' sticks": screening of olfactory performance. Rhinology (1996) 2.17
Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. Ann Oncol (2007) 2.15
Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med (1990) 2.15
Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol (2009) 2.12
The same tyrosine-based inhibition motif, in the intracytoplasmic domain of Fc gamma RIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation. Immunity (1995) 2.12
Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann Oncol (2010) 2.11
Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med (1998) 2.08
Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. Ann Oncol (2002) 2.03
Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. Proc Natl Acad Sci U S A (2000) 2.03
Benefit of cytoreductive nephrectomy in metastatic RCC: do we learn from retrospective studies and small prospective studies? Ann Oncol (2011) 2.03
Overview of interleukin-18: more than an interferon-gamma inducing factor. J Leukoc Biol (1998) 2.00
BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer Group. Am J Hum Genet (1997) 1.91
Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol (2010) 1.91
Molecular characterization and biological function of the movement protein of tobacco mosaic virus in transgenic plants. Proc Natl Acad Sci U S A (1990) 1.89
IL-18 regulates IL-1beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. Proc Natl Acad Sci U S A (2000) 1.86
Primary chemotherapy for operable breast cancer: incidence and prognostic significance of ipsilateral breast tumor recurrence after breast-conserving surgery. J Clin Oncol (2001) 1.84
Nonunion of the mandible: an analysis of contributing factors. J Oral Maxillofac Surg (2000) 1.83
Cell-mediate cytotoxicity in vitro of human lymphocytes against a tissue culture melanoma cell line (igr3). J Immunol (1975) 1.82
Expressed sequences as candidates for a novel tumor suppressor gene at band 13q14 in B-cell chronic lymphocytic leukemia and mantle cell lymphoma. Oncogene (1998) 1.81
Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease. Neurology (2012) 1.78
Response rate accuracy in oncology trials: reasons for interobserver variability. Groupe Français d'Immunothérapie of the Fédération Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol (1997) 1.77
Neuropathic shoulder arthropathy (Charcot joint) associated with syringomyelia. Neurology (1998) 1.73
Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet (1993) 1.72
Prognostic value of intratumoral interferon gamma messenger RNA expression in invasive cervical carcinomas. J Natl Cancer Inst (1998) 1.71
Familial invasive breast cancers: worse outcome related to BRCA1 mutations. J Clin Oncol (2000) 1.71
Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors. J Clin Invest (1995) 1.70
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol (1997) 1.67
Emergency physician workload: a time study. Ann Emerg Med (1993) 1.66
Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. Ann Oncol (2010) 1.65
A universal spine tester for in vitro experiments with muscle force simulation. Eur Spine J (1994) 1.65
Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial. Br J Cancer (2013) 1.65
Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer (1994) 1.60
Tyrosine-containing motif that transduces cell activation signals also determines internalization and antigen presentation via type III receptors for IgG. Nature (1992) 1.60
Rates and predictors of remission and recovery during 3 years in 392 never-treated patients with schizophrenia. Acta Psychiatr Scand (2008) 1.59
The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. J Med Genet (2009) 1.59
The Roseto effect: a 50-year comparison of mortality rates. Am J Public Health (1992) 1.58
Serum soluble interleukin-2 receptor concentrations as an independent prognostic marker in head and neck cancer. Lancet (2001) 1.58
Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. Ann Oncol (2009) 1.57
Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev (2011) 1.55
A case control study of multiple myeloma at four nuclear facilities. Ann Epidemiol (2000) 1.55
The human genes for GM-CSF and IL 3 are closely linked in tandem on chromosome 5. Blood (1988) 1.54
Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. Mol Psychiatry (2008) 1.54
Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Invest (1994) 1.53
No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int J Cancer (1998) 1.52
Coincidence of seminoma and sarcoidosis: a myth or fact? Ann Oncol (1998) 1.51
Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol (1992) 1.50
Characterization and function of T cell Fc gamma receptor. Immunol Rev (1981) 1.50
A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci U S A (2001) 1.49
Differential modulation of stimulatory and inhibitory Fc gamma receptors on human monocytes by Th1 and Th2 cytokines. J Immunol (2001) 1.48
T-cell hybrids bear Fcgamma receptors and secrete suppressor immunoglobulin binding factor. Nature (1979) 1.47
Transplacental transmission of HTLV-III virus. N Engl J Med (1985) 1.47
Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol (1998) 1.46
Soluble Fc gamma receptors. J Leukoc Biol (1993) 1.45
Indocyanine green guided laser photocoagulation in patients with occult choroidal neovascularisation. Br J Ophthalmol (1999) 1.44
Role of interaction of CD2 molecules with lymphocyte function-associated antigen 3 in T-cell recognition of nominal antigen. Proc Natl Acad Sci U S A (1990) 1.44
Heat and moisture exchanger vs heated humidifier during long-term mechanical ventilation. A prospective randomized study. Chest (1991) 1.43
Protracted continuous infusion of 5-fluorouracil in combination with doxorubicin, vincristine, and oral cyclophosphamide in advanced breast cancer. Cancer Invest (1996) 1.42
Cloning of a leucine-zipper protein recognized by the sera of patients with antibody-associated paraneoplastic cerebellar degeneration. Proc Natl Acad Sci U S A (1991) 1.41
Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. J Natl Cancer Inst (1989) 1.40
Liver transplantation after organ preservation with normothermic extracorporeal perfusion. Ann Surg (2001) 1.40
The separate determination of human pepsin and gastricsin. Proc Soc Exp Biol Med (1966) 1.40
Circadian rhythm disorders in manic-depressives. Biol Psychiatry (1978) 1.40
Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol (1995) 1.39
Mobility impairments and use of preventive services in women with multiple sclerosis: observational study. BMJ (2001) 1.38
[Immunonutritive enteral feeding in the critically ill]. Anaesthesist (2002) 1.38
Concurrent administration of rhesus rotavirus tetravalent (RRV-TV) vaccine with pentavalent diphtheria-pertussis-tetanus-Haemophilus influenzae beta-inactivated polio and hepatitis B vaccines. Acta Paediatr (1999) 1.38
Suppression of in vitro antibody synthesis by immunoglobulin-binding factor. J Exp Med (1975) 1.37
Altered function of the tobacco mosaic virus movement protein in a hypersensitive host. Virology (1991) 1.37